Month: November 2014

ONL Therapeutics Receives Phase II SBIR Grant from National Eye Institute for Development of Novel Retinal Disease Treatment ANN ARBOR, MI – November 12, 2014 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced that the company has been awarded a $1.37 million Small…

SBIR Award, $1M Investment Get ONL Therapeutics to Clinical Trials Xconomy Detroit – 11/12/14 by Sarah Schmid ONL Therapeutics, a University of Michigan spin-out biopharmaceutical startup working on sight-preserving therapies for retinal diseases, announced today that it has won a $1.3 million Small Business Innovation Research (SBIR) Phase II award from the National Eye Institute. Read the Article